TY - JOUR
T1 - Renal protective effects of gamma-mangostin in streptozotocin-induced diabetic mice
AU - Husen, Saikhu Akhmad
AU - Salamun,
AU - Ansori, Arif Nur Muhammad
AU - Hayaza, Suhailah
AU - Susilo, Raden Joko Kuncoroningrat
AU - Winarni, Dwi
AU - Darmant, Win
N1 - Publisher Copyright:
© 2020, Indian Journal of Forensic Medicine and Toxicology. All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - This study was aimed to investigate the ability of gamma-mangostin to reduce plasma blood urea nitrogen (BUN) and creatinine and ameliorates the impaired renal proximal tubular cells in diabetic mice. Antioxidant assay was conducted by using male BALB/c mice. Mice were divided into two groups, they were normal control (KN) and streptozotocin-induced diabetic mice. Streptozotocin (STZ) induction was performed using multiple low-dose of 30 mg/kg body weight injected for five consecutive days. Diabetic mice have divided into three subgroups; diabetic control (KD), diabetic mice treated with acarbose (KA), and diabetic mice treated with gamma-mangostin. The gamma-mangostin treatment group was categorized based on the dose given; P1 (1 mg/kg BW), P2 (2 mg/kg BW), and P3 (4 mg/kg BW). Interestingly, gamma-mangostin administration was found to be able to lower plasma BUN and creatinine and ameliorate the impaired renal proximal tubular cells in diabetic mice significantly. Therefore, gamma-mangostin has demonstrated high antioxidant activity. The proof suggests that gamma-mangostin is a lead compound candidate for clinical management or prevent diabetes mellitus.
AB - This study was aimed to investigate the ability of gamma-mangostin to reduce plasma blood urea nitrogen (BUN) and creatinine and ameliorates the impaired renal proximal tubular cells in diabetic mice. Antioxidant assay was conducted by using male BALB/c mice. Mice were divided into two groups, they were normal control (KN) and streptozotocin-induced diabetic mice. Streptozotocin (STZ) induction was performed using multiple low-dose of 30 mg/kg body weight injected for five consecutive days. Diabetic mice have divided into three subgroups; diabetic control (KD), diabetic mice treated with acarbose (KA), and diabetic mice treated with gamma-mangostin. The gamma-mangostin treatment group was categorized based on the dose given; P1 (1 mg/kg BW), P2 (2 mg/kg BW), and P3 (4 mg/kg BW). Interestingly, gamma-mangostin administration was found to be able to lower plasma BUN and creatinine and ameliorate the impaired renal proximal tubular cells in diabetic mice significantly. Therefore, gamma-mangostin has demonstrated high antioxidant activity. The proof suggests that gamma-mangostin is a lead compound candidate for clinical management or prevent diabetes mellitus.
KW - Antioxidant activity
KW - Diabetes mellitus
KW - Gamma-mangostin
UR - http://www.scopus.com/inward/record.url?scp=85088010804&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85088010804
SN - 0973-9122
VL - 14
SP - 1221
EP - 1226
JO - Indian Journal of Forensic Medicine and Toxicology
JF - Indian Journal of Forensic Medicine and Toxicology
IS - 3
ER -